Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 300 Boston Scientific Way MARLBOROUGH MA 01752-1291 |
Tel: | N/A |
Website: | https://www.bostonscientific.com/en-US/Home.html |
IR: | See website |
Key People | ||
Michael F. Mahoney Chairman of the Board, President, Chief Executive Officer | Emily Woodworth Senior Vice President, Chief Accounting Officer, Controller | Daniel J. Brennan Chief Financial Officer, Executive Vice President |
Wendy Carruthers Executive Vice President - Human Resources | Arthur Crosswell Butcher Executive Vice President, Group President, MedSurg and Asia Pacific | Joseph M. Fitzgerald Executive Vice President, Group President - Cardiology |
Ian T. Meredith Executive Vice President, Global Chief Medical Officer | Jeffrey B. Mirviss Executive Vice President and President - Peripheral Interventions | John Bradley Sorenson Executive Vice President - Global Operations | Eric Francis Yves Thepaut Executive Vice President and President - Europe, Middle East and Africa |
Business Overview |
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. |
Financial Overview |
For the fiscal year ended 31 December 2023, Boston Scientific Corporation revenues increased 12% to $14.24B. Net income applicable to common stockholders increased from $642M to $1.57B. Revenues reflect Cardiovascular segment increase of 13% to $8.82B, MedSurg segment increase of 10% to $5.42B, United States segment increase of 10% to $8.43B, EMEA (Europe, Middle East and Africa) segment increase of 13% to $2.86B. |
Employees: | 48,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $109,101M as of Dec 31, 2023 |
Annual revenue (TTM): | $14,240M as of Dec 31, 2023 |
EBITDA (TTM): | $4,079M as of Dec 31, 2023 |
Net annual income (TTM): | $1,571M as of Dec 31, 2023 |
Free cash flow (TTM): | $1,764M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $8,237M as of Dec 31, 2023 |
Shares outstanding: | 1,469,895,391 as of Mar 8, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |